Jacques-P. Tremblay
Chercheur universitaire
Axe Neurosciences
Thérapie génique et moléculaire
Biotechnologies médicales
Publications
View all-
article Siddika A, Husseiny FE, Rousseau J, Tremblay JP
Prime Editing Mediated Generation and Correction of the mdx5cv Mutation Restores Dystrophin Expression in Myoblasts
Int J Mol Sci 27 (15), 2026.
-
article Iwe IA, Liu FX, Corsano A, da Silva SJR, Doucet J, Singh S, Lamothe G, Zayani R, Nguyen J, Matthews Q, Vigar JRJ, Bayat P, Simchi M, Bozovicar K, Charania M, Panfilov S, Kelly P, Cai R, Hubbard BP, Li X, Mazzulli T, Tremblay JP, Zhao Y, Green AA, Li Z, Yao S, Pardee K
RAPID: evaluation of Cas12a protospacer nicking and chimeric reporters for PAM-independent RNA and DNA diagnostics
Nucleic Acids Res 54 (14), 2026.
-
article Siddika A, Rousseau J, Veillette F, Bouchard C, Lu Y, Tremblay JP
Gene Editing Strategies for Duchenne Muscular Dystrophy: From Molecular Mechanisms to Clinical Translation
Cells 15 (10), 2026.
Projects
- In vivo correction by CRISPR PRIME editing of mutations responsible for Duchenne Muscular Dystrophy, from 2023-12-01 to 2026-11-30
- Correction by Prime editing of point mutations responsible for Cystic fibrosis in Quebec province, from 2025-10-03 to 2028-03-31
- Development of a Prime Editing-Based Therapy for Alzheimer’s Disease, from 2026-01-01 to 2029-01-31
- Modification par Prime editing du gène MYOC pour prévenir le développement du glaucome héréditaire, from 2025-10-01 to 2026-09-30
- Correction par Prime Editing des Mutations Ponctuelles Responsables de l'ARSACS, from 2026-08-01 to 2027-07-31
- Removal of the GAA repeat with the CRISPR/Cas9 system in Friedreich patient cells and in the YG8sR mouse model, from 2019-10-01 to 2024-09-30
- Development of a rapid and simple test to detect the COVID-19 variants that can be used in remote areas and developing countries, from 2021-06-01 to 2025-03-31
- Development of an AAV library, from 2022-04-01 to 2024-09-30
- Correcting point mutations responsible for Dysferlinopathy using Prime Editing, from 2023-08-01 to 2025-01-31
- Développement d'un traitement pour prévenir ou ralentir la progression de la maladie d'Alzheimer, from 2023-11-08 to 2026-04-30
- Correction of point mutations responsible for Dysferlinopathy using Prime Editing Renouvellement 2025-2026, from 2025-02-01 to 2026-08-31